LiTime, a global pioneer in energy innovation, showcased its latest lithium power solutions for landscaping and outdoor ...

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...

Bristol-Myers Squibb's has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for ...

With these advantages, LiTime lithium batteries are gradually surpassing lead-acid batteries, not only reducing long-term ...

Friends, I’ve gotten myself into a pickle and I need some help. A few years back, I decided to get into solar power by ...

Positive top-line results from the Phase III EMERGENT-4 and EMERGENT-5 open-label trials evaluating the long-term efficacy, safety, and tolerability of Cobenfy (xanomeline and trospium chloride) in ...